Perspectives of Women with Breast Cancer and Healthcare Providers Participating in an Adherence-Enhancing Program for Adjuvant Endocrine Therapy: A Qualitative Study

Overview

Journal Curr Oncol

Publisher MDPI

Date 2025 Jan 24

PMID 39851961

Authors

Veronique Turcotte

Laurence Guillaumie

Martine Lemay

Anne Dionne

Julie Lemieux

Angeline Labbe

Carolyn Gotay

Line Guenette

Sophie Lauzier

Affiliations

Soon will be listed here.

Abstract

Background: Adjuvant endocrine therapy (AET) is prescribed for 5-10 years to women with hormone-sensitive breast cancer to prevent recurrence. However, a significant proportion of women do not adhere to AET. We developed SOIE, a one-year program designed to enhance the AET experience and adherence. SOIE was pilot-tested in a mixed-methods randomized controlled trial. This report presents the experience of women and healthcare providers (HCPs) with SOIE.

Methods: A descriptive qualitative study using semi-structured interviews and thematic analysis was conducted with 20 women and 7 HCPs who participated in the program.

Results: Most women and HCPs reported high satisfaction with the program. Women felt it addressed their need for information and strategies to manage side effects. They felt supported and developed a more positive attitude toward AET, which contributed to their intention to pursue AET. They perceived that the program helped them navigate the AET experience and reduced their stress or fear regarding AET. HCPs corroborated these benefits.

Conclusions: Findings suggest that SOIE can enhance the experience and motivation to pursue the AET treatment by meeting important needs for information, side-effects management, and psycho-emotional support. Programs like SOIE can have benefits beyond adherence by improving patients' well-being during this crucial long-term treatment.

References

Shaver J . The State of Telehealth Before and After the COVID-19 Pandemic. Prim Care. 2022; 49(4):517-530. PMC: 9035352. DOI: 10.1016/j.pop.2022.04.002. View

Arch J, Crespi C, Levin M, Genung S, Nealis M, Mitchell J . Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors. Ann Behav Med. 2022; 56(8):856-871. PMC: 9345183. DOI: 10.1093/abm/kaab118. View

Assan O, Memoli V, Guillaumie L, Turcotte V, Lemay M, Dionne A . Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results. J Cancer Surviv. 2024; . DOI: 10.1007/s11764-024-01599-y. View

Paranjpe R, John G, Trivedi M, Abughosh S . Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2018; 174(2):297-305. DOI: 10.1007/s10549-018-05073-z. View

Moon Z, Moss-Morris R, Hunter M, Carlisle S, Hughes L . Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017; 11:305-322. PMC: 5328144. DOI: 10.2147/PPA.S126651. View

Xu H, Zhang X, Wang D, Xu L, Wang A . Factors influencing medication-taking behaviour with adjuvant endocrine therapy in women with breast cancer: A qualitative systematic review. J Adv Nurs. 2019; 76(2):445-458. DOI: 10.1111/jan.14253. View

Ma H, Lu Y, Marchbanks P, Folger S, Strom B, McDonald J . Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res. 2013; 15(5):R90. PMC: 3978823. DOI: 10.1186/bcr3486. View

Graetz I, Hu X, Kocak M, Krukowski R, Anderson J, Waters T . Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2024; 7(6):e2417873. PMC: 11211959. DOI: 10.1001/jamanetworkopen.2024.17873. View

Graneheim U, LUNDMAN B . Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004; 24(2):105-12. DOI: 10.1016/j.nedt.2003.10.001. View

10.

Ell K, Vourlekis B, Xie B, Nedjat-Haiem F, Lee P, Muderspach L . Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer. 2009; 115(19):4606-15. PMC: 2749894. DOI: 10.1002/cncr.24500. View

11.

Huang H, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E . Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005; 58(6):611-6. PMC: 1770673. DOI: 10.1136/jcp.2004.022772. View

12.

Murphy C, Bartholomew L, Carpentier M, Bluethmann S, Vernon S . Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012; 134(2):459-78. PMC: 3607286. DOI: 10.1007/s10549-012-2114-5. View

13.

Graham C, Ellison R, Hall L, Clark J, McNaught E, Green S . A pilot randomised controlled trial of acceptance and commitment therapy for medication decision-making and quality of life in women with breast cancer: The ACTION trial. Psychooncology. 2024; 33(5):e6349. DOI: 10.1002/pon.6349. View

14.

Humphries B, Collins S, Guillaumie L, Lemieux J, Dionne A, Provencher L . Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions. Pharmacy (Basel). 2018; 6(2). PMC: 6024955. DOI: 10.3390/pharmacy6020053. View

15.

Lambert L, Balneaves L, Howard A, Gotay C . Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2017; 167(3):615-633. DOI: 10.1007/s10549-017-4561-5. View

16.

Eliassen F, Blafjelldal V, Helland T, Hjorth C, Holland K, Lode L . Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. 2023; 23(1):625. PMC: 10320891. DOI: 10.1186/s12885-023-11122-8. View

17.

Camire-Bernier E, Nidelet E, Baghdadli A, Demers G, Boulanger M, Brisson M . Parents' Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study. Curr Oncol. 2021; 28(6):4377-4391. PMC: 8628767. DOI: 10.3390/curroncol28060372. View

18.

Yussof I, Mohd Tahir N, Hatah E, Mohamed Shah N . Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review. Breast. 2022; 62:22-35. PMC: 8818734. DOI: 10.1016/j.breast.2022.01.012. View

19.

Toivonen K, Williamson T, Carlson L, Walker L, Campbell T . Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review. Cancers (Basel). 2021; 13(1). PMC: 7794693. DOI: 10.3390/cancers13010107. View

20.

AlOmeir O, Patel N, Donyai P . Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. Support Care Cancer. 2020; 28(11):5075-5084. PMC: 7546985. DOI: 10.1007/s00520-020-05585-9. View